{"url":"https://whatshealthyandwhy.com/citicoline/cognitive-function-and-neuroprotection","path":"/citicoline/cognitive-function-and-neuroprotection","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/citicoline/cognitive-function-and-neuroprotection.json","markdown":"https://whatshealthyandwhy.com/citicoline/cognitive-function-and-neuroprotection.md"},"topic":{"slug":"citicoline","name":"Citicoline","url":"https://whatshealthyandwhy.com/citicoline"},"slug":"cognitive-function-and-neuroprotection","order":1,"title":"Brain Energy, Memory, and Neuroprotection","question":"Does citicoline improve memory and focus?","answer":"Citicoline likely gives modest memory gains in older adults and better attention in adolescent males, but trials are small and short.","description":"How citicoline (CDP-choline) builds brain cell membranes, sharpens attention, and protects the aging mind","confidence":3,"confidenceNote":"Two small RCTs (100 older adults, 40 adolescent males) and a Cochrane review of 14 trials agree, but trials were short.","evidenceSummary":{"rctCount":2,"observationalCount":1,"metaAnalysisCount":2,"totalParticipants":"~2,000","replicated":true,"newestStudyYear":2023},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Memory trials used 500 mg a day for 12 weeks; the attention trial in adolescents used 250 mg for 28 days [1][5].","Generic CDP-choline is the same active compound as branded Cognizin (used in most trials) and costs less."],"cautions":["Side effects are rare and mild: occasional nausea, headache or insomnia at higher doses.","It may theoretically boost cholinergic medications, so check with your doctor or pharmacist if you take them.","Long-term benefit in healthy adults is unproven; most trials ran 12 weeks or less."],"simpleText":"Citicoline — also called CDP-choline — is a naturally occurring compound your brain makes to build and repair cell membranes. As a supplement it raises both acetylcholine and dopamine activity, which translates into sharper attention and better memory, particularly in people whose recall has begun to slip with age. [1][2] It has been prescribed in Europe and Japan for decades under names like Somazina, giving it one of the longest and cleanest safety records of any nootropic. For healthy people looking to protect cognitive function, it stands out for combining structural brain support with immediate attentional benefits.","mediumText":"How Citicoline Works\n\nCiticoline is an intermediate in the body's main pathway for making phosphatidylcholine — the phospholipid that forms roughly 30% of all brain cell membranes. When you take it orally, it cleaves into two components: choline and cytidine. Each does different work.\n\nThe choline fraction is a direct precursor to acetylcholine, the neurotransmitter essential for memory formation, learning, and sustained attention. The cytidine fraction is converted in the body to uridine, a nucleotide that supports dopamine receptor sensitivity and the growth of new synaptic connections. This dual mechanism distinguishes citicoline from other choline supplements: it supports both the cholinergic system (memory, focus) and the dopaminergic system (motivation, executive function) simultaneously. [2]\n\nCiticoline also enhances mitochondrial energy output in neurons, reduces the release of free fatty acids after ischemic injury, and has measurable anti-inflammatory effects via cytokine modulation. These properties make it useful not just for everyday cognitive support but also in recovery from stroke and traumatic brain injury.\n\nCiticoline vs. Other Choline Supplements\n\nCiticoline is often compared to two other choline supplements:\n\nAlpha-GPC raises acetylcholine more aggressively and is better studied for acute cognitive enhancement and growth hormone secretion. It has less evidence for the membrane-building and dopaminergic effects citicoline provides. See our Alpha-GPC page.\n\nCholine bitartrate is primarily a methyl donor used for liver health and methylation support. It raises choline levels but does not contribute cytidine or uridine. See our Choline page.\n\nCiticoline's advantage is breadth: it provides membrane precursors, dopaminergic support, and cholinergic support in a single compound with an excellent safety profile.\n\nDosage and Practical Notes\n\nClinical trials have used doses ranging from 250 mg to 1,000 mg per day. Most cognitive trials used 500 mg/day, often split into two doses. Effects on attention and working memory can appear within 2–4 weeks; structural benefits to brain membrane integrity accrue over months of consistent use.\n\nThe branded form Cognizin® is the most extensively studied and is used in most published trials. Generic CDP-choline is widely available at lower cost; while less studied as a standalone brand, the active compound is identical.\n\nCiticoline is generally well tolerated. Reported side effects across decades of clinical use are rare and mild: occasional nausea, headache, or insomnia at higher doses. It has no known serious drug interactions, though it may theoretically potentiate cholinergic medications.","deepText":"Evidence Review\n\nMemory in Healthy Older Adults\n\nThe most methodologically rigorous trial in healthy people enrolled 100 adults aged 50–85 with self-reported memory complaints but no dementia diagnosis (PMID 33978188). Participants received 500 mg/day Cognizin® citicoline or placebo for 12 weeks. The citicoline group showed significantly greater improvement in composite memory scores (p < 0.05), with the strongest effect on episodic memory — the variety of recall that typically declines earliest in aging. This trial is notable for using a population without diagnosed cognitive impairment, demonstrating that citicoline's benefits are not confined to diseased brains. [1]\n\nMild Cognitive Impairment\n\nA 2023 prospective observational study (PMID 36818199) followed 349 patients with mild cognitive impairment over 9 months. Patients receiving citicoline 1,000 mg/day showed significantly better preservation of MMSE scores compared to untreated controls. The conversion rate to dementia was 18% in the citicoline group versus 32% in controls — a clinically meaningful difference even in an observational design. This study could not be randomized for ethical reasons, which limits causal inference, but the size of the effect across a large sample is notable. [4]\n\nCochrane Meta-Analysis\n\nA systematic review covering 14 randomized controlled trials and 1,051 patients with cognitive impairment from multiple causes (PMID 10796523) found \"modest but significant beneficial effects\" on memory and behavior at follow-up periods of 1–3 months. The evidence was strongest for vascular cognitive impairment. The review's main limitation is the short study durations and the heterogeneous patient populations across included trials. The authors specifically called for longer trials to determine whether benefits persist. Despite its age, this remains the most comprehensive controlled analysis of citicoline for cognitive impairment. [2]\n\nAttention in Healthy Adolescents\n\nA 2015 randomized trial (PMID 26179181) assigned 40 healthy adolescent males to 250 mg/day citicoline or placebo for 28 days. The citicoline group showed significant improvements in sustained attention and fewer omission errors on the Continuous Performance Test — a measure specifically sensitive to attentional lapses rather than processing speed. The finding is significant because it extends citicoline's attentional benefits to a young, neurologically intact population, not just older adults with existing impairment. [5]\n\nGlaucoma and Retinal Neuroprotection\n\nCiticoline has an unusual second evidence base in ophthalmology. Glaucoma damages retinal ganglion cells through a process involving glutamate excitotoxicity and oxidative stress — mechanisms citicoline is proposed to counter by stabilizing cell membranes and reducing excitatory neurotransmitter toxicity.\n\nA 2015 review by Roberti et al. (PMID 26633368) critically summarized the current evidence on citicoline in glaucoma, which the authors describe as a neurodegenerative disease involving ocular and visual brain structures, for which neuroprotection has been proposed as a valid therapeutic option in patients who keep progressing despite well-controlled intraocular pressure. [3]\n\nA 2023 systematic review of 10 studies including 424 glaucoma patients (PMID 37768938) found no significant differences in intraocular pressure, visual field mean deviation (MD 24-2), retinal nerve fibre layer (RNFL) or pattern electroretinogram (PERG) P50-N95 amplitude between patients receiving citicoline and the control group, and no improvement from baseline to the last follow-up. The reviewers concluded that there is a lack of sufficient evidence to support that citicoline slows the progression of glaucoma. [6]\n\nStrength of Evidence\n\nCiticoline has a stronger evidence base than the majority of nootropic supplements. It has multiple double-blind RCTs, a Cochrane systematic review, decades of prescription use in Europe and Japan, and an independent body of ophthalmological research. Its main evidence gaps are long-duration trials in healthy adults (most trials run 12 weeks or less) and head-to-head comparisons against other choline compounds. The safety record across all populations and decades of clinical use is consistently excellent.","deepTruncated":false,"references":[{"id":"1","title":"Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","authors":"Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F","year":2021,"journal":"Journal of Nutrition","pmid":"33978188","url":"https://pubmed.ncbi.nlm.nih.gov/33978188/"},{"id":"2","title":"Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly","authors":"Fioravanti M, Yanagi M","year":2000,"journal":"Cochrane Database of Systematic Reviews","pmid":"10796523","url":"https://pubmed.ncbi.nlm.nih.gov/10796523/"},{"id":"3","title":"Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives","authors":"Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, Oddone F","year":2015,"journal":"International Journal of Molecular Sciences","pmid":"26633368","url":"https://pubmed.ncbi.nlm.nih.gov/26633368/"},{"id":"4","title":"Role of Citicoline in Patients With Mild Cognitive Impairment","authors":"Bermejo PE, Dorado R, Zea-Sevilla MA","year":2023,"journal":"Neuroscience Insights","pmid":"36818199","url":"https://pubmed.ncbi.nlm.nih.gov/36818199/"},{"id":"5","title":"The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males","authors":"McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, et al.","year":2015,"journal":"Journal of Attention Disorders","pmid":"26179181","url":"https://pubmed.ncbi.nlm.nih.gov/26179181/"},{"id":"6","title":"Efficacy of citicoline as a supplement in glaucoma patients: A systematic review","authors":"Prinz J, Prokosch V, Liu H, Walter P, Fuest M, Migliorini F","year":2023,"journal":"PLoS ONE","pmid":"37768938","url":"https://pubmed.ncbi.nlm.nih.gov/37768938/"}],"wordCount":1073,"source":{"path":"src/content/topics/citicoline/cognitive-function-and-neuroprotection.md"},"citeAs":"“Does citicoline improve memory and focus?.” What's Healthy and Why. https://whatshealthyandwhy.com/citicoline/cognitive-function-and-neuroprotection","notice":"General information backed by peer-reviewed research, not medical advice."}